1055 related articles for article (PubMed ID: 25063516)
1. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease.
Stanek LM; Yang W; Angus S; Sardi PS; Hayden MR; Hung GH; Bennett CF; Cheng SH; Shihabuddin LS
J Huntingtons Dis; 2013; 2(2):217-28. PubMed ID: 25063516
[TBL] [Abstract][Full Text] [Related]
2. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
3. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
5. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
6. Huntingtin inclusions do not down-regulate specific genes in the R6/2 Huntington's disease mouse.
Sadri-Vakili G; Menon AS; Farrell LA; Keller-McGandy CE; Cantuti-Castelvetri I; Standaert DG; Augood SJ; Yohrling GJ; Cha JH
Eur J Neurosci; 2006 Jun; 23(12):3171-5. PubMed ID: 16820007
[TBL] [Abstract][Full Text] [Related]
7. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.
Stanek LM; Sardi SP; Mastis B; Richards AR; Treleaven CM; Taksir T; Misra K; Cheng SH; Shihabuddin LS
Hum Gene Ther; 2014 May; 25(5):461-74. PubMed ID: 24484067
[TBL] [Abstract][Full Text] [Related]
8. Differential D1 and D2 receptor-mediated effects on immediate early gene induction in a transgenic mouse model of Huntington's disease.
Spektor BS; Miller DW; Hollingsworth ZR; Kaneko YA; Solano SM; Johnson JM; Penney JB; Young AB; Luthi-Carter R
Brain Res Mol Brain Res; 2002 Jun; 102(1-2):118-28. PubMed ID: 12191502
[TBL] [Abstract][Full Text] [Related]
9. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease.
Southwell AL; Kordasiewicz HB; Langbehn D; Skotte NH; Parsons MP; Villanueva EB; Caron NS; Østergaard ME; Anderson LM; Xie Y; Cengio LD; Findlay-Black H; Doty CN; Fitsimmons B; Swayze EE; Seth PP; Raymond LA; Frank Bennett C; Hayden MR
Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282695
[TBL] [Abstract][Full Text] [Related]
10. Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is modulated by PP1 and PP2A.
Metzler M; Gan L; Mazarei G; Graham RK; Liu L; Bissada N; Lu G; Leavitt BR; Hayden MR
J Neurosci; 2010 Oct; 30(43):14318-29. PubMed ID: 20980587
[TBL] [Abstract][Full Text] [Related]
11. Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT.
Moreno CL; Ehrlich ME; Mobbs CV
Neurobiol Dis; 2016 Jan; 85():25-34. PubMed ID: 26485309
[TBL] [Abstract][Full Text] [Related]
12. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
[TBL] [Abstract][Full Text] [Related]
13. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.
Gharami K; Xie Y; An JJ; Tonegawa S; Xu B
J Neurochem; 2008 Apr; 105(2):369-79. PubMed ID: 18086127
[TBL] [Abstract][Full Text] [Related]
14. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease.
Chan EY; Luthi-Carter R; Strand A; Solano SM; Hanson SA; DeJohn MM; Kooperberg C; Chase KO; DiFiglia M; Young AB; Leavitt BR; Cha JH; Aronin N; Hayden MR; Olson JM
Hum Mol Genet; 2002 Aug; 11(17):1939-51. PubMed ID: 12165556
[TBL] [Abstract][Full Text] [Related]
15. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
16. Mitogen- and stress-activated protein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptional dysregulation and striatal death.
Roze E; Betuing S; Deyts C; Marcon E; Brami-Cherrier K; Pagès C; Humbert S; Mérienne K; Caboche J
FASEB J; 2008 Apr; 22(4):1083-93. PubMed ID: 18029446
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease.
Tang TS; Chen X; Liu J; Bezprozvanny I
J Neurosci; 2007 Jul; 27(30):7899-910. PubMed ID: 17652581
[TBL] [Abstract][Full Text] [Related]
18. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease.
Schmidt ME; Buren C; Mackay JP; Cheung D; Dal Cengio L; Raymond LA; Hayden MR
BMC Biol; 2018 Jun; 16(1):58. PubMed ID: 29945611
[TBL] [Abstract][Full Text] [Related]
19. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.
Wu J; Ryskamp DA; Liang X; Egorova P; Zakharova O; Hung G; Bezprozvanny I
J Neurosci; 2016 Jan; 36(1):125-41. PubMed ID: 26740655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]